Header Logo

Connection

ALAN SWANN to Double-Blind Method

Back to Details
This is a "connection" page, showing publications ALAN SWANN has written about Double-Blind Method.
ALAN SWANN
Connection Strength
0.737
Double-Blind Method
  1. Norepinephrine and impulsivity: effects of acute yohimbine. Psychopharmacology (Berl). 2013 Sep; 229(1):83-94.
    View in: PubMed
    Score: 0.074
  2. High-order brain interactions during ketamine-induced state changes: A functional marker of response in late-life treatment-resistant depression? Transl Psychiatry. 2026 Jul 04; 16(1).
    View in: PubMed
    Score: 0.046
  3. Acute yohimbine increases laboratory-measured impulsivity in normal subjects. Biol Psychiatry. 2005 May 15; 57(10):1209-11.
    View in: PubMed
    Score: 0.043
  4. Effects of the KCNQ (Kv7) Channel Opener Ezogabine on Resting-State Functional Connectivity of Striatal Brain Reward Regions, Depression, and Anhedonia in Major Depressive Disorder: Results From a Randomized Controlled Trial. Biol Psychiatry. 2025 Oct 01; 98(7):568-577.
    View in: PubMed
    Score: 0.042
  5. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology. 2002 Apr; 26(4):530-6.
    View in: PubMed
    Score: 0.034
  6. Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial. Neuropsychopharmacology. 2022 04; 47(5):1088-1095.
    View in: PubMed
    Score: 0.034
  7. Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial. Depress Anxiety. 2021 11; 38(11):1108-1119.
    View in: PubMed
    Score: 0.033
  8. Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. Am J Psychiatry. 2021 05 01; 178(5):437-446.
    View in: PubMed
    Score: 0.032
  9. Low dose zolmitriptan as a 5-HT neuroendocrine challenge agent in humans. Psychoneuroendocrinology. 2000 Aug; 25(6):607-18.
    View in: PubMed
    Score: 0.031
  10. Mania: differential effects of previous depressive and manic episodes on response to treatment. Acta Psychiatr Scand. 2000 Jun; 101(6):444-51.
    View in: PubMed
    Score: 0.030
  11. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry. 1999 Aug; 156(8):1264-6.
    View in: PubMed
    Score: 0.029
  12. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry. 1997 Jan; 54(1):37-42.
    View in: PubMed
    Score: 0.024
  13. A randomized, double-blind, placebo-controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence. Alcohol Clin Exp Res. 2014 Jul; 38(7):2113-8.
    View in: PubMed
    Score: 0.020
  14. The role of cortisol and psychopathy in the cycle of violence. Psychopharmacology (Berl). 2013 Jun; 227(4):661-72.
    View in: PubMed
    Score: 0.018
  15. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry. 1992 Jan; 149(1):108-11.
    View in: PubMed
    Score: 0.017
  16. Stress, depression, and mania: relationship between perceived role of stressful events and clinical and biochemical characteristics. Acta Psychiatr Scand. 1990 Apr; 81(4):389-97.
    View in: PubMed
    Score: 0.015
  17. A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. Alcohol Clin Exp Res. 2009 Nov; 33(11):1863-9.
    View in: PubMed
    Score: 0.014
  18. Evaluation of heterogeneity in pharmacotherapy trials for drug dependence: a Bayesian approach. Am J Drug Alcohol Abuse. 2009; 35(2):95-102.
    View in: PubMed
    Score: 0.014
  19. Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Am J Drug Alcohol Abuse. 2007; 33(3):367-78.
    View in: PubMed
    Score: 0.012
  20. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry. 2006 Oct; 67(10):1501-10.
    View in: PubMed
    Score: 0.012
  21. Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs. 2006; 20(3):219-31.
    View in: PubMed
    Score: 0.011
  22. Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo. Neuropsychopharmacology. 2005 Oct; 30(10):1932-9.
    View in: PubMed
    Score: 0.011
  23. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry. 2005 Mar; 162(3):621-4.
    View in: PubMed
    Score: 0.011
  24. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2005 Mar; 66(3):323-30.
    View in: PubMed
    Score: 0.011
  25. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ. 2005 Apr 16; 330(7496):874.
    View in: PubMed
    Score: 0.011
  26. Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level. Psychopharmacology (Berl). 1985; 87(2):147-51.
    View in: PubMed
    Score: 0.010
  27. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry. 2004 Jan; 65(1):114-9.
    View in: PubMed
    Score: 0.010
  28. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology. 2003 Jul; 28(7):1374-82.
    View in: PubMed
    Score: 0.009
  29. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology. 2003 Jun; 28(6):1186-97.
    View in: PubMed
    Score: 0.009
  30. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry. 2003 Mar; 64(3):288-94.
    View in: PubMed
    Score: 0.009
  31. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2002 Dec; 63(12):1148-55.
    View in: PubMed
    Score: 0.009
  32. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry. 2000 Nov; 61(11):841-50.
    View in: PubMed
    Score: 0.008
  33. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000 May; 57(5):481-9.
    View in: PubMed
    Score: 0.008
  34. Ritanserin in the treatment of cocaine dependence. Biol Psychiatry. 1997 Nov 15; 42(10):932-40.
    View in: PubMed
    Score: 0.006
  35. Effect size of efficacy measures comparing divalproex, lithium and placebo in acute mania. Depress Anxiety. 1997; 6(1):26-30.
    View in: PubMed
    Score: 0.006
  36. Maintenance clinical trials in bipolar disorder: design implications of the divalproex-lithium-placebo study. Psychopharmacol Bull. 1997; 33(4):693-9.
    View in: PubMed
    Score: 0.006
  37. Relation of serum valproate concentration to response in mania. Am J Psychiatry. 1996 Jun; 153(6):765-70.
    View in: PubMed
    Score: 0.006
  38. Drug-induced actions on brain neurotransmitter systems and changes in the behaviors and emotions of depressed patients. Neuropsychopharmacology. 1994 Oct; 11(2):89-100.
    View in: PubMed
    Score: 0.005
  39. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA. 1994 Mar 23-30; 271(12):918-24.
    View in: PubMed
    Score: 0.005
  40. Sociodemographic and prior clinical course characteristics associated with treatment response in depressed patients. J Psychiatr Res. 1988; 22(3):227-37.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.